Merck Sues Sandoz Over Plan For Generic Emend

Law360, New York (March 2, 2009, 12:00 AM EST) -- Merck & Co. Inc. has sued Sandoz Inc., Novartis Pharmaceutical Corp.'s generics unit, over its plan to make a generic version of the anti-nausea drug Emend, alleging that the generic drug would infringe four of Merck's patents.

According to Merck's complaint, filed Friday in the U.S. District Court for the District of New Jersey, Sandoz told Merck in a letter on Jan. 15 that it had filed an abbreviated new drug application with the U.S. Food and Drug Administration to make a generic version of Emend,...
To view the full article, register now.